Target intelligence / Profile preview

JAMM domain zinc metalloprotease (JAMM (JAB1/MPN/Mov34 metalloenzyme))

Target
JAMM (JAB1/MPN/Mov34 metalloenzyme)
Molecular classification
Enzyme, Metalloprotease, Deubiquitinating enzyme (DUB), Isopeptidase
01

Overview

The JAMM domain zinc metalloprotease is a unique class of deubiquitinating enzymes (DUBs) characterized by a zinc-dependent metalloprotease mechanism and a conserved sequence motif (EX(n)HS/THX(7)SXXD). These enzymes are critical in the removal of ubiquitin (and ubiquitin-like proteins such as NEDD8) from substrate proteins, a process essential for regulating the ubiquitin-proteasome pathway, protein turnover, and proteasome activity. The JAMM domain (also known as the JAB1/MPN/Mov34 motif) is found in multiple essential eukaryotic proteins, such as Rpn11 (in the 19S proteasome) and Csn5 (in the COP9 signalosome), where it orchestrates the terminal steps of protein degradation by removing ubiquitin prior to substrate proteolysis[6][4][1]. The mechanism involves catalytic hydrolysis of the isopeptide bond via a zinc-mediated nucleophilic attack, similar to but structurally distinct from classical thermolysin-like metalloproteases[1][3][6]. Dysregulation and mutation of JAMM domain proteins are implicated in tumorigenesis and other disorders, making the JAMM domain an actively pursued therapeutic target in oncology and immunology, with small-molecule inhibitors under development[4][6][1].

Other names
JAB1/MPN/Mov34 metalloenzymeMPN+ isopeptidaseJAMM motif proteaseZn^2+-dependent JAMM metalloproteaseJAMM metalloprotease
02

Mechanism of action

Competitive inhibition at the catalytic zinc site of the JAMM domain; Coordination or chelation of Zn^2+ in the active site to block enzymatic activity; Interference with protein deubiquitination/deNEDDylation, thereby affecting protein degradation pathways

03

Biological functions

Cleavage of isopeptide bonds (deubiquitination and deNEDDylation)Regulation of ubiquitin-proteasome systemControl of protein turnover and signal transductionSelective hydrolysis of ubiquitin and ubiquitin-like protein conjugatesRegulation of COP9 signalosome and 19S proteasome activities
04

Disease associations

Cancer (notably, involved in tumorigenesis and frequently discussed as a target in cancer therapy)Immunological disordersCould have roles in neurodegenerative diseases and other conditions linked to protein homeostasis disruption
05

Safety considerations

Broad inhibition of the proteasome or signalosome can lead to adverse effects due to general impairment of protein degradation, impacting cell viability and functionPotential cytotoxicity, particularly in non-cancer cellsOff-target effects from inhibitors due to structural similarity with other metalloproteases
06

Interacting drugs

Capzimin (Rpn11 inhibitor)

2 more in the full profile.

07

Biomarkers

Increased expression or activity of JAMM domain proteins (e.g., Rpn11, CSN5) may serve as biomarkers for proteasome or signalosome activity, and potentially for sensitivity to related inhibitors in cancerUbiquitin or NEDD8-conjugated protein levels as indirect monitoring biomarkers

Beyond the preview

Go deeper on JAMM domain zinc metalloprotease (JAMM (JAB1/MPN/Mov34 metalloenzyme)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on JAMM domain zinc metalloprotease (JAMM (JAB1/MPN/Mov34 metalloenzyme)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call